Inhibrx Biosciences, Inc. (INBX) — Cash Flow-to-Debt Ratio
Inhibrx Biosciences, Inc. (INBX) has a Cash Flow-to-Debt Ratio of -0.19x as of March 2026, meaning its operating cash flow of $-38.03 Million could theoretically repay 0% of its total liabilities ($205.00 Million) in one year. See Inhibrx Biosciences, Inc. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Inhibrx Biosciences, Inc. Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Inhibrx Biosciences, Inc. across 10 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Inhibrx Biosciences, Inc..
Annual Cash Flow-to-Debt Ratio for Inhibrx Biosciences, Inc. (2016–2025)
Year-by-year debt coverage analysis for Inhibrx Biosciences, Inc.. Check Inhibrx Biosciences, Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.94x | $-129.79 Million | $138.49 Million | ▲ +77.3% |
| 2024 | -4.12x | $-194.41 Million | $47.18 Million | ▼ -463.5% |
| 2023 | -0.73x | $-193.31 Million | $264.39 Million | ▼ -47.6% |
| 2022 | -0.50x | $-115.30 Million | $232.82 Million | ▲ +39.5% |
| 2021 | -0.82x | $-80.32 Million | $98.07 Million | ▼ -16.6% |
| 2020 | -0.70x | $-47.97 Million | $68.27 Million | ▼ -163.0% |
| 2019 | -0.27x | $-32.08 Million | $120.06 Million | ▲ +21.7% |
| 2018 | -0.34x | $-23.09 Million | $67.63 Million | ▲ +27.8% |
| 2017 | -0.47x | $-18.75 Million | $39.67 Million | ▲ +47.7% |
| 2016 | -0.90x | $-18.11 Million | $20.03 Million | — |